Copenhagen Master Observational Trial

Plain-language summary

This observational study aims to better understand disease in patients with non-small cell lung cancer or breast cancer by collecting data such as whole genome sequencing. It is enrolling patients aged 18 and older who are suitable for treatment with curative or palliative intent and can read and understand Danish. This study has no assigned phase and is still recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Rigshospitalet, Denmark

Intervention

NO intervention

Start date

8/1/2021

Estimated completion

12/31/2027

Countries

Denmark

Related genes

Locations

• Copenhagen, Denmark

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients (≥ 18 years of age) with diagnosis of NSCLC or breast cancer amenable to medical or radiation therapy with curative or palliative intent
* Evidence of a personally signed and dated informed consent form document indicating that the patient has been informed of all pertinent aspects of the study
* Able to read and understand Danish
* Willing and able to complete collection of data including WGS

Exclusion Criteria:

* Patient with breast cancer initiating adjuvant systemic therapy
* In the judgment of the investigator, the patient's life expectancy is fewer than 3 months at the time of diagnosis of NSCLC or breast cancer